SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
LUNG reported Third Quarter 2026 results. The price and volatility reaction is pending.
LUNGearnings

Earnings reactions, page 11

Pulmonx Corporation (LUNG) Q3 FY2026 earnings

October 28, 2026 · SharpeIQ Research Desk

Reported results

  • Achieved GAAP worldwide revenue of $22.8 million in the third quarter of 2026.
  • Delivered GAAP U.S. revenue of $14.9 million in the third quarter of 2026.
  • Delivered GAAP international revenue of $7.9 million in the third quarter of 2026.
  • Realized GAAP gross margin of 76% in the third quarter of 2026.
  • Reported a GAAP net loss of $8.4 million in the third quarter of 2026.
  • Reported a non-GAAP Adjusted EBITDA loss of $3.5 million in the third quarter of 2026.

Guidance

  • Full year 2026 revenue expected to be in the range of $90 million to $92 million.
  • Full year 2026 gross margin expected to be approximately 77%.
  • Full year 2026 total operating expenses expected to fall within the range of $108 million to $109 million.
  • Cash, cash equivalents, and marketable securities expected to decrease by approximately $22 million for the full year 2026.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-10-27 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →